Verapamil, and Its Metabolite Norverapamil, Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated Tolerance to Multiple Anti-tubercular Drugs
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Drug tolerance likely represents an important barrier to tuberculosis treatment shortening. We previously implicated the Mycobacterium tuberculosis efflux pump Rv1258c as mediating macrophage-induced tolerance to rifampicin and intracellular growth. In this study, we infected the human macrophage-like cell line THP-1 with drug-sensitive and drug-resistant M. tuberculosis strains and found that tolerance developed to most antituberculosis drugs, including the newer agents moxifloxacin, PA-824, linezolid, and bedaquiline. Multiple efflux pump inhibitors in clinical use for other indications reversed tolerance to isoniazid and rifampicin and slowed intracellular growth. Moreover, verapamil reduced tolerance to bedaquiline and moxifloxacin. Verapamil's R isomer and its metabolite norverapamil have substantially less calcium channel blocking activity yet were similarly active as verapamil at inhibiting macrophage-induced drug tolerance. Our finding that verapamil inhibits intracellular M. tuberculosis growth and tolerance suggests its potential for treatment shortening. Norverapamil, R-verapamil, and potentially other derivatives present attractive alternatives that may have improved tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“Consequently, there has been considerable excitement about the recently developed compounds PA824 and bedaquiline (TMC-207) [6, 7].”
Black Pepper and its Pungent Principle-Piperine: A Review of Diverse Physiological Effects
Srinivasan, K. (2007) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390601062054 · Cited by 821
Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803899200 · Cited by 364 · cited 1×
“Bedaquiline has been shown to be active against both replicating and nonreplicating bacteria in culture [8].”
Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis
Yajko, D. M., Madej, J. J., Lancaster, M. V., Sanders, C. A., Cawthon, V. L., Gee, B., Babst, A., & Hadley, W. K. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.9.2324-2327.1995 · Cited by 209
Cited by
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
Host Evasion and Exploitation Schemes of Mycobacterium tuberculosis
Cambier, C. J., Falkow, S., & Ramakrishnan, L. (2014) · Cell · doi:10.1016/j.cell.2014.11.024 · Cited by 426
Self-citationAntimicrobial Activity and Resistance: Influencing Factors
Li, J., Xie, S., Ahmed, S., Wang, F., Gu, Y., Zhang, C., Chai, X., Wu, Y., Cai, J., & Cheng, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00364 · Cited by 266
Annunziato, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235844 · Cited by 256
Roca, F. J., Whitworth, L. J., Redmond, S., Jones, A. A., & Ramakrishnan, L. (2019) · Cell · doi:10.1016/j.cell.2019.08.004 · Cited by 233
“Finally, we note that the LTCC inhibitor verapamil also inhibits mycobacterial drug tolerance through its action on bacterial drug efflux pumps by a different mechanism (Adams et al., 2014; Adams et al., 2011; Gupta et al., 2013).”
BackgroundSelf-citation
Metadata
- Authors
- Adams, K. N., Szumowski, J. D., & Ramakrishnan, L.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-14
- Volume
- 210
- Issue
- 3
- Pages
- 456-466
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2139104845
- Cited by
- 136
- References
- 4
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Verapamil, and Its Metabolite Norverapamil, Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated Tolerance to Multiple Anti-tubercular Drugs. https://app.cochat.ai/papers/10.1093/infdis/jiu095
- The paper
- Adams, K. N., Szumowski, J. D., & Ramakrishnan, L. (2014). Verapamil, and Its Metabolite Norverapamil, Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated Tolerance to Multiple Anti-tubercular Drugs. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiu095
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.